DFG-out Mode of Inhibition by an Irreversible Type-1 Inhibitor Capable of Overcoming Gate-Keeper Mutations in FGF Receptors.
Huang, Z., Tan, L., Wang, H., Liu, Y., Blais, S., Deng, J., Neubert, T.A., Gray, N.S., Li, X., Mohammadi, M.(2015) ACS Chem Biol 10: 299-309
- PubMed: 25317566 
- DOI: 10.1021/cb500674s
- Primary Citation of Related Structures:  
4QQ5, 4QQJ, 4QQT, 4QRC - PubMed Abstract: 
Drug-resistance acquisition through kinase gate-keeper mutations is a major hurdle in the clinic. Here, we determined the first crystal structures of the human FGFR4 kinase domain (FGFR4K) alone and complexed with ponatinib, a promiscuous type-2 (DFG-out) kinase inhibitor, and an oncogenic FGFR4K harboring the V550L gate-keeper mutation bound to FIIN-2, a new type-1 irreversible inhibitor ...